Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

n Therapeutics. "We are also very pleased with the safety profile demonstrated by Contrave thus far. We look forward to the results from the remaining Phase 3 trials which will further examine the efficacy, safety and tolerability of Contrave with less intensive behavior modification as well as in patients with Type 2 diabetes patients."

Patient enrollment has been completed in the three other Phase 3 trials. Orexigen expects to announce top-line results from these trials in mid-2009 and, pending additional positive results, submit a New Drug Application (NDA) with the FDA in late 2009.

Study Details and Results

The objective of this NB-302 trial was to determine the additional weight loss and health benefits of Contrave when added to an intensive diet and exercise program. The trial included the most intensive behavior modification regimen of the Phase 3 program for Contrave, which resulted, as expected, in a high degree of weight loss among placebo patients.

This 56-week, double-blind, placebo-controlled trial conducted at nine U.S. centers evaluated the efficacy and safety of Contrave (32mg naltrexone SR/360mg bupropion SR) compared to placebo in 793 obese patients who participated in an intense behavioral program consisting of counseling, diet and exercise. Patients enrolled in the trial were randomized on a 3 to 1 ratio between Contrave and placebo, and had a body mass index (BMI) of 30 to 45, or as low as 27 in the presence of cardiometabolic co-morbidities. Drug dosages were initially titrated over a four week period and then administered over 52 weeks of therapy at full dose. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

    Efficacy results from this trial are summarized in the following table:

                          Intent-To-Treat*            
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The participants committed to not ... spending their own time adjusting, tweaking and testing virtual ... were ready for judging. , “I enjoyed being involved ... leader. “The entries showed a commendable range exploring ... of the print medium and the creativity of the ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... Award winning unified communications (UC) and ... collaboration bundles that combine next generation communication technologies. ... for low, flat rate fees. With four ... optimized solutions to meet their technology needs. , ... minutes (1K, 5K, 10K increments) or audio minutes ...
(Date:10/1/2014)... 2014 TeselaGen Biotechnology has ... to expand their bioCAD/CAM software suite, which uses ... The Small Business Innovation Research Phase II grant will ... exclusive license from the Lawrence Berkeley National Laboratory. j5 ... an LBNL laboratory that develops alternative fuel technologies for ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
... , , , ... , Current studies show that only four ... point of care. By 2019, the Congressional Budget Office (CBO) estimates ... to about 90 percent , EHRs will create ...
... ATLANTA and LONDON, Sept. 10 CryoLife ... device and cardiovascular tissue processing company, today announced the first clinical ... received CE mark approval in August 2009. BioFoam was used in ... to promote hemostasis (a complex process that stops bleeding) by sealing ...
Cached Biology Technology:Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 4CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5
(Date:9/30/2014)... LIVERMORE, Calif. The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama,s BRAIN (Brain ... new research effort to revolutionize our understanding of ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... using marijuana, new research, involving mice and published in ... of Leukocyte Biology , suggests that just because ... That,s because a team of Italian scientists have found ... damage to the immune system. This damage may result ... multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis in ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... Advanced Iris Recognition Algorithm Detects and Compensates for ... ... Neurotechnology today,announced the addition of VeriEye iris recognition technology ... products. VeriEye SDK features an advanced iris recognition,algorithm that ...
... Stanley, Inc. (NYSE:,SXE), a leading provider of ... government, announced today that it has entered into ... an,engineering, intelligence operations and information technology services,company. The ... cash,subject to certain working capital and other adjustments ...
... AMBER Alert Safety Centers,Inc. announced today that the Company ... Fair, to be held at the Meadowlands Sport,Complex in East ... the entire family featuring rides, free entertainment, games, exhibits,shopping and ... Patterson -- Chief Executive Officer ...
Cached Biology News:New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 2AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 3
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... Principle: The sulfidoleukotrienes ... are products of arachidonic acid ... In the past, they were ... of Anaphylaxis (SRS-A)". They are ...
... the condition in which a lack of ... the various antioxidants. Oxidative stress appears ... several diseases, including artherosclerosis, chronic inflammatory diseases, ... antioxidant systems that are very important for ...
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
Biology Products: